Aptevo Therapeutics Stock (NASDAQ:APVO)
Previous Close
$0.17
52W Range
$0.14 - $21.56
50D Avg
$0.33
200D Avg
$2.76
Market Cap
$1.59M
Avg Vol (3M)
$6.48M
Beta
5.15
Div Yield
-
APVO Company Profile
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Performance
Peer Comparison
Ticker | Company |
---|---|
HOTH | Hoth Therapeutics, Inc. |
MGTA | Dianthus Therapeutics, Inc. |
NTRB | Nutriband Inc. |
ACHL | Achilles Therapeutics plc |
LRMR | Larimar Therapeutics, Inc. |
LGVN | Longeveron Inc. |
REVB | Revelation Biosciences, Inc. |
IVVD | Invivyd, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
KRON | Kronos Bio, Inc. |
PASG | Passage Bio, Inc. |
VRAX | Virax Biolabs Group Limited |
RNXT | RenovoRx, Inc. |
CYCN | Cyclerion Therapeutics, Inc. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
ATXI | Avenue Therapeutics, Inc. |
ADXN | Addex Therapeutics Ltd |